Humanized Bispecific Antibody Neutralizing Both Sclerostin and Dickkopf-1 (Angitia Biopharmaceuticals)

N/A

Report date: 2022/11/18 16:08:48

Base Information

Drug NameHumanized Bispecific Antibody Neutralizing Both Sclerostin and Dickkopf-1 (Angitia Biopharmaceuticals)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionSclerostin inhibitorsDickkopf-related protein 1 inhibitors

TargetsSclerostinDickkopf-related protein 1

Therapy Area/IndicationsOsteogenesis Imperfecta

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesAngitia Biopharmaceuticals (Guangzhou) Ltd

China Registration ClassN/A

Develop Information

Active CompaniesAngitia Biopharmaceuticals (Guangzhou) Ltd

Inactive CompaniesN/A

Active IndicationsOsteogenesis Imperfecta

Inactive IndicationsN/A

Other Information

ATC CodeN/A